#152046

pJEK1 Alpha-Synuclein Vector

Please Enter Your Email ID
Email ID

Cat. #152046

pJEK1 Alpha-Synuclein Vector

Cat. #: 152046

Availability: Please enquire for quantities and pricing

Target: Alpha-synuclein

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Dr Fiona Benson

Institute: Lancaster University

Tool Details
Target Details
Application Details
References

Tool Details

*FOR RESEARCH USE ONLY

  • Tool name: pJEK1 Alpha-Synuclein Vector
  • Research fields: Neurobiology
  • Description: pJEK1 is a derivative of pET15b with the human alpha-synuclein open reading frame cloned in via the Ndel and BamHI restriction sites. In this construct alpha-synuclein is expressed as a fusion protein with a six His tag. 2004 FASEB paper: this alpha-synuclein protein available here is cited as source (2) in the Methods section.
  • Additional notes: Alpha-synuclein is expressed predominantly in the brain, where it is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.

Target Details

  • Target: Alpha-synuclein

Application Details

  • Application notes: pJEK1 is a derivative of pET15b with the human alpha-synuclein open reading frame cloned in via the Ndel and BamHI restriction sites. In this construct alpha-synuclein is expressed as a fusion protein with a six His tag. 2004 FASEB paper: this alpha-synuclein protein available here is cited as source (2) in the Methods section.

References

  • El-Agnaf et al. 2004. FASEB J. 18(11):1315-7. PMID: 15180968.
  • A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.